Antisense oligonucleotides targeting the 5’ splicing sites of ERBB2 i14e can sensitize trastuzumab therapy, suggesting that combined treatment of ERBB2 i14e ASOs with trastuzumab or trastuzumab-drug conjugates holds great promising benefit for cancer patients expressing ERBB2 i14e. Here, ERBB2 is linked to cancer.